

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



MedSci Healthcare Holdings Limited

梅斯健康控股有限公司

(Incorporated in the Cayman Islands with limited liability)

(Stock Code: 2415)

INSIDE INFORMATION POSITIVE PROFIT ALERT

This announcement is made by MedSci Healthcare Holdings Limited (the “**Company**”, together with its subsidiaries, the “**Group**”) pursuant to Rule 13.09(2)(a) of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the “**Listing Rules**”) and the Inside Information Provisions (as defined under the Listing Rules) under Part XIVA of the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong).

The board (the “**Board**”) of directors (the “**Directors**”) of the Company wishes to inform the shareholders of the Company (the “**Shareholders**”) and potential investors that, based on a preliminary review of the unaudited consolidated management accounts of the Group for the year ended 31 December 2023 and an assessment of the information currently available to the Board, the Group is expected to record a profit attributable to the Shareholders of not less than RMB50 million for the year ended 31 December 2023 as compared to a net loss attributable to the Shareholders recorded for the year ended 31 December 2022. The profit turnaround of the Group was mainly attributable to the following: (i) against the backdrop of anti-corruption measures in medical industry, doctors became more career-focused, at the same time, pharmaceutical and medical device companies began to transform their existing marketing models, enabling the Company to expand its business scale; (ii) enhancement of application of artificial intelligence within the Group which improved its production efficiency; and (iii) fair value gain on convertible redeemable preferred shares.

As at the date of this announcement, the Company is still in the course of preparing the results of the Company for the year ended 31 December 2023. The information contained in this announcement is only based on the preliminary assessment by the Board of the unaudited consolidated management accounts of the Group for the year ended 31 December 2023, which have not been reviewed by the Company's auditors, nor confirmed by the audit committee of the Company. Such financial information will be subject to finalisation and necessary adjustments. The results of the Company for the year ended 31 December 2023 are expected to be announced by the Company by the end of March 2024. Shareholders and potential investors are advised to read the annual results announcement of the Company when it is published.

Shareholders and potential investors should exercise caution when dealing in the shares of the Company.

By order of the Board
MedSci Healthcare Holdings Limited
梅斯健康控股有限公司
Dr. Zhang Fabao
Chairman of the Board and Executive Director

Hong Kong, 11 March 2024

As at the date of this announcement, the Board of Directors comprises Dr. Zhang Fabao, Dr. Li Xinmei, Mr. Fan Jie and Mr. Wang Shuai, as executive Directors; Mr. Hu Xubo and Mr. Yan Shengfeng, as non-executive Directors; and Ms. Liu Tao, Mr. Yu Mingyang and Mr. Lau Yiu Kwan Stanley, as independent non-executive Directors.